CRISPR THERAPEUTICS AG Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CRISPR THERAPEUTICS AG stock issued during period, value, new issues for the quarter ending 2025-09-30 was $275.32M, a 4532.64% increase year-over-year.
- CRISPR THERAPEUTICS AG stock issued during period, value, new issues for the quarter ending 2025-06-30 was $70.61M.
- CRISPR THERAPEUTICS AG stock issued during period, value, new issues for the quarter ending 2025-03-31 was $8.64M, a 96.88% decline year-over-year.
- CRISPR THERAPEUTICS AG stock issued during period, value, new issues for the quarter ending 2024-09-30 was $5.94M.
- CRISPR THERAPEUTICS AG stock issued during period, value, new issues for fiscal 2025 was $468.04M, a 57.22% increase from fiscal 2024.
- CRISPR THERAPEUTICS AG stock issued during period, value, new issues for fiscal 2024 was $297.70M, a 819.00% increase from fiscal 2023.
- CRISPR THERAPEUTICS AG stock issued during period, value, new issues for fiscal 2023 was $32.39M, a 3239.59% increase from fiscal 2022.
- CRISPR THERAPEUTICS AG stock issued during period, value, new issues for fiscal 2022 was $970.00K, a 99.56% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $468.04M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $275.32M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $70.61M 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $8.64M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $297.70M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $5.94M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $277.15M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $32.39M 10-K · filed 2026-02-12 | |
| 2022-12-31 | $970.00K 10-K · filed 2025-02-11 | |
| 2022-09-30 | $970.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $222.18M 10-K · filed 2024-02-21 | |
| 2021-03-31 | $222.18M 10-Q · filed 2022-11-01 | |
| 2020-12-31 | $973.38M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $494.59M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $82.19M 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $414.79M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $68.66M 10-Q · filed 2020-10-28 | |
| 2019-06-30 | $28.11M 10-Q · filed 2020-10-28 | |
| 2019-03-31 | $23.47M 10-Q · filed 2020-10-28 | |
| 2018-12-31 | $307.05M 10-K · filed 2021-02-16 | |
| 2018-09-30 | $184.46M 10-Q · filed 2019-10-28 | |
| 2018-03-31 | $122.60M 10-Q · filed 2019-10-28 | |
| 2016-12-31 | $88.66M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |